Randomized, double-blind, placebo-controlled trial of the efficacy and tolerability of a new isoindoline derivative (DN-2327) in generalized anxiety

Human Psychopharmacology

Volumn 12, Issue 5, 1997, Pages 445-452

  Linden, M ^a   Hadler, D ^b   Hofmann, S ^b  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

^b Takeda Pharma GmbH   (Germany)

Author keywords

Anxiolytic drugs; DN 2327; Generalized anxiety; Isoindoline derivative; Placebo controlled clinical trial

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; ANXIOLYTIC AGENT; BENZODIAZEPINE RECEPTOR; DIAZEPAM; FLUNITRAZEPAM; PAZINACLONE; PLACEBO;

ANXIETY NEUROSIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RECEPTOR BINDING; FATIGUE; FEMALE; HAMILTON SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VERTIGO;

EID: 0030814903     PISSN: 08856222     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-1077(199709/10)12:5<445::AID-HUP887>3.0.CO;2-2     Document Type: Article

References (33)

1. Ballenger, J. C., McDonald, S., Noyes, R. Jr., Rickels, K., Woods, S. W., Patin, J., Lydiard, B., Garvey, M., Cook, B., Goodard, A. W. and Schweizer, E. (1992). The first double-blind, placebo-controlled trial of a partial benzodiazepine agonist, abecarnil (ZK 112-119), in generalized anxiety disorder. Advances in Biochemistry and Psychopharmacology, 47, 431-447.
2. Binz, U. and Wendt, G. (1986). KUSTA, Kurz-Skala Stimmung/Antrieb. In: Internationale Skalen für Psychiatrie, CIPS (Ed.), Beltz, Weinheim.
3. Bradwejn, J. (1993). Benzodiazepines for the treatment of panic disorder and generalized anxiety disorder: clinical issues and future directions. Canadian Journal of Psychiatry, 38, Suppl. 4, 109-113.
4. Brown, T. A., Barlow, D. H. and Liebowitz, M. R. (1994). The empirical basis of generalized anxiety disorder. American Journal of Psychiatry, 151, 1272-1280.
5. Cormack, M. A., Qwens, R. G. and Dewey, M. E. (1989). Reducing Benzodiazepine Consumption. Springer, Berlin.
6. Cutler, N. R., Hesselink, J. M. and Sramek, J. J. (1994). A phase II multicenter dose-finding, efficacy and safety trial of ipsapirone in outpatients with generalized anxiety disorder. Progress in Neuropsychopharmacology and Biological Psychiatry, 18, 447-463.
7. DeJonge, F., Swinkels, J., Tuynman-Quatt, H. and Jonkers, F. (1989). A comparative study of suriclone, lorazepam and placebo in anxiety disorder. Pharmacopsychiatry, 22, 266-271.
8. Geiselmann, B. and Linden, M. (1991). Prescription and intake patterns in long-term and ultra-long-term benzodiazepine treatment in primary care practice. Pharmacopsychiatry, 24, 55-61.
9. Hamilton, M. (1986). HAMA, Hamilton Anxiety Scale. In: Internationale Skalen für Psychiatrie, CIPS (Ed.), Beltz, Weinheim.
10. Holden, J. D., Hughes, I. M. and Tree, A. (1994). Benzodiazepine prescribing and withdrawal for 3234 patients in 15 general practices. Family Practice, 11, 358-362.
11. Hollister, L. E., Müller-Oerlinghausen, B., Rickels, K. and Shader, R. I. (1993). Clinical uses of benzodiazepines. Journal of Clinical Pharmacology, 13 Suppl. 1, 1-169.
12. Katz, R. J., Landau, P. S., Lott, M., Bystritsky, A., Diamond, B., Hoehn-Saric, R., Rosenthal, M. and Weise, C. (1993). Serotonergic (5-HT2) mediation of anxiety-therapeutic effects of serazepine in generalized anxiety disorder. Biological Psychiatry, 34, 41-44.
13. King, D. J. (1992). Benzodiazepines, amnesia and sedation: Theoretical and clinical issues and controversies. Human Psychopharmacology, 7, 479-487.
14. Klein, E., Colin, V., Stolk, J. and Lenox, R. H. (1994). Alprazolam withdrawal in patients with panic disorder and generalized anxiety disorder: vulnerability and effect of carbamazepine. American Journal of Psychiatry, 151, 1760-1766.
15. Lader, M. (1988). Buspirone: A New Introduction to the Treatment of Anxiety. Royal Society of Medical Services, New York.
16. Lehmann, E. (1989). The dose-effect relationship of 0.5, 1.0, and 1.5 mg fluspirilene on anxious patients. Neuropsychobiology, 21, 197-204.
17. Linden, M. (1993). Epidemiologie von Angst- und Panikerkrankungen. In: Angst- und Panikerkrankungen, Kasper, S. and Möller H. J. (Hrsg.), Socio Medico Verlag, Gräfelfing.
18. Linden, M. and Gothe, H. (1993). Benzodiazepine Substitution in medical practice: Analysis of pharmacoepidemiological data based on expert interviews. Pharmacopsychiatry, 26, 107-113.
19. Melander, A., Henricson, K., Stenberg, P., Löwenhielm, P., Malmvik, J., Sternebring, B., Kaij, L. and Bergdahl, U. (1991). Anxiolytic-hypnotic drugs: Relationship between prescribing, abuse and suicide. European Journal of Clinical Pharmacology, 41, 525-529.
20. Merz, W. A. and Ballmer, U. (1983). Symptoms of the barbiturate/benzodiazepine withdrawal syndrome in healthy volunteers: Standardized assessment by a newly developed self-rating scale. Journal of Psychoactive Drugs, 15, 71-84.
21. Morton, S. V. and Lader, M. H. (1992). Alpidem and lorazepam in the treatment of patients with anxiety disorders: Comparison of efficacy and rebound. Human Psychopharmacology, 7, 239-248.
22. NIMH (1986). CGI, Clinical Global Impressions. In: Internationale Skalen für Psychiatrie, CIPS (Ed.), Beltz, Weinheim.
23. Petursson, H. and Lader, M. (1984). Dependence on Tranquilizers. Oxford University Press, Oxford.
24. Rapee, R. M. (1991). Generalized Anxiety Disorder: A review of clinical features and theoretical concepts. Clinical Psychology Review, 11, 419-440.
25. Rickels, K., Downing, R., Schweizer, E. and Hassman, H. (1993). Antidepressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison of imipramine, trazodone, and diazepam. Archives of General Psychiatry, 50, 884-895.
26. Rickels, K., Schweizer, E., Csanalosi, I., Case, W. G. and Chung, H. (1988). Long-term treatment of anxiety and risk of withdrawal. Prospective comparison of clorazepate and buspirone. Archives of General Psychiatry, 45, 444-450.
27. Roy-Byrne, P., Wingerson, D., Cowley, D. and Dager, S. (1993). Psychopharmacologic treatment of panic, generalized anxiety disorder, and social phobia. Psychiatric Clinics of North America, 16, 719-735.
28. Sacchetti, E., Zerbini, O., Banfi, F. and Tansella, M. (1994). Overlap of buspirone with lorazepam, diazepam and bromazepam in patients with generalized anxiety disorder: Findings from a controlled, multicentre, double-blind study. Human Psychopharmacology, 9, 409-422.
29. Schweizer, E. E., Rickels, K. and Lucki, I. (1986). Resistance to the anti-anxiety effect of buspirone in patients with a history of benzodiazepine use. New England Journal of Medicine, 314, 719-720.
30. Solomon, K. and Hart, R. (1978). Pitfalls and prospects in clinical research on antianxiety drugs: Benzodiazepines and placebo. A research review. Journal of Clinical Psychiatry, 39, 823-831.
31. Sramek, J. J., Robinson, R. E., Suri, A. and Cutler, N. R. (1995). Efficacy trial of the 5-HT2 antagonist MDL 11,939 in patients with generalized anxiety disorder. Clinical Psychopharmacology, 15, 20-22.
32. Wittchen, H. U., Zhao, S., Kessler, R. C. and Eaton, W. W. (1994). DSM-III-R Generalized Anxiety Disorder in the National Comorbidity Survey. Archives of General Psychiatry, 51, 355-364.
33. Wurthmann, C., Klieser, E. and Lehmann, E. (1995). Interaktion von therapeutischen Wirkungen und Nebenwirkungen in der Pharmakotherapie generalisierter Angststorungen mit niedrigdosiertem Fluspirilen. Fortschritte der Neurology Psychiatrie, 63, 72-77.